Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures

American Journal of Neuroradiology

Volumn 34, Issue 4, 2013, Pages 700-706

  Hussein, H M ^a   Emiru, T ^a   Georgiadis, A L ^a   Qureshi, A I ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PARACETAMOL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE; TIROFIBAN; WARFARIN;

BLOOD CLOTTING PARAMETERS; DOSE RESPONSE; ENDOVASCULAR SURGERY; HEMOSTASIS; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS THROMBECTOMY; POINT OF CARE TESTING; REVIEW; STENT THROMBOSIS; THERAPY RESISTANCE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER;

BLOOD COAGULATION TESTS; BLOOD PLATELETS; CEREBRAL ARTERIES; ENDOVASCULAR PROCEDURES; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; THROMBOEMBOLISM;

EID: 84876732072     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2963     Document Type: Review

References (62)

1. Qureshi AI, Luft AR, Sharma M, et al. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures. Part II. Clinical aspects and recommendations. Neurosurgery 2000;46:1360-75, discussion 1375-76
2. Krpski WC, Bass A, Kelly AB, et al. Heparin-resistant thrombus formation by endovascular stents in baboons: Interruption by a synthetic antithrombin. Circulation 1990;82:570-77 (Pubitemid 20257836)
3. Ries T, Buhk J-H, Kucinski T, et al. Intravenous administration of acetylsalicylic acid during endovascular treatment of cerebral aneurysms reduces the rate of thromboembolic events. Stroke 2006;37:1816-21 (Pubitemid 44297735)
4. Riedel C, Tietke M, Alfke K, et al. Subacute stent thrombosis in intracranial stenting. Stroke 2009;40:1310-14
5. Sutton JM, Ellis SG, Roubin GS, et al. Major clinical events after coronary stenting: The multicenter registry of acute and elective Gianturco-Roubin stent placement-the Gianturco-Roubin Intracoronary Stent Investigator Group. Circulation 1994;89:1126-37
6. VerifyNow aspirin assay [package insert]. San Diego, California: Accumetrics.
7. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 1999;99:620-25 (Pubitemid 29077360)
8. Ang L, Mahmud E. Monitoring oral antiplatelet therapy: Is it justified? Ther Adv Cardiovasc Dis 2008;2:485-96
9. Nielsen HL, Kristensen SD, Thygesen SS, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res 2008;123:267-73
10. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel- Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008;51:2028-33 (Pubitemid 351689056)
11. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277-84 (Pubitemid 44918092)
12. VerifyNow P2Y12 Assay [Package Insert]. San Diego, California: Accumetrics.
13. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-78 (Pubitemid 32521967)
14. Lakkis NM, George S, Thomas E, et al. Use of ICHOR-platelet works to assess platelet function in patients treated withGPIIb/IIIa inhibitors. Catheter Cardiovasc Interv 2001;53:346-51 (Pubitemid 32622564)
15. Carville DG, Schleckser PA, Guyer KE, et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 1998;30:171-77 (Pubitemid 29152672)
16. Helena Laboratories. Plateletworks: Platelet Function Kits. http://www.helena.com/plateletworks.html. Accessed January 2011
17. van Werkum JW, Kleibeuker M, Postma S, et al. A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol 2010;140:123-26
18. Linnemann B, Schwonberg J, Rechner AR, et al. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010;89:597-605
19. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 1995; 21(suppl 2):106-12
20. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases. Blood 1998;91:1325-31 (Pubitemid 28086886)
21. Homoncik M, Jilma B, Hergovich N, et al. Monitoring of aspirin (ASPIRIN) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316-21 (Pubitemid 30093238)
22. Koscielny J, von Tempelhoff GF, Ziemer S, et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004;10:155-66 (Pubitemid 38490084)
23. Fattorutto M, Pradier O, Schmartz D, et al. Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass? Br J Anaesth 2003;90:692-93 (Pubitemid 36592347)
24. Marshall PW, Williams AJ, Dixon RM, et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997;44:151-55 (Pubitemid 27327067)
25. Golanski J, Pluta J, Baraniak J, et al. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists-in vitro experience. Clin Chem Lab Med 2004;42:25-29 (Pubitemid 38401464)
26. Kotzailias N, Elwischger K, Sycha T, et al. Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. J Stroke Cerebrovasc Dis 2007;16:199-202 (Pubitemid 47369190)
27. Pidcock M, Harrison P. Can the PFA-100 be modified to detect P2Y12 inhibition? J Thromb Haemost 2006;4:1424-26
28. Koessler J, Kobsar AL, Rajkovic MS, et al. The new INNOVANCE(R) PFA P2Y cartridge is sensitive to the detection of the P2Y receptor inhibition. Platelets 22:19-25
29. Varon D, Dardik R, Shenkman B, et al. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997;85:283-94 (Pubitemid 27143804)
30. Varon D, Lashevski I, Brenner B, et al. Cone and plate(let) analyzer: Monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998;135:S187-93 (Pubitemid 28237293)
31. Knobler H, Savion N, Shenkman B, et al. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 1998;90:181-90 (Pubitemid 28352671)
32. Kenet G, Lubetsky A, Shenkman B, et al. Cone and platelet analyser (CPA): A new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998;101:255-59 (Pubitemid 28261111)
33. Shenkman B, Inbal A, Tamarin I, et al. Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition. Br J Haematol 2003;120:597-604 (Pubitemid 36255859)
34. Savion N, Shenkman B, Tamarin I, et al. Transient adhesion refractoriness of circulating platelets under shear stress: The role of partial activation and microaggregate formation by suboptimal ADP concentration. Br J Haematol 2001;112:1055-61 (Pubitemid 32322936)
35. Spectre G, Brill A, Gural A, et al. A new point-of-care method for monitoring anti-platelet therapy: Application of the cone and plate-(let) analyzer. Platelets 2005;16:293-99 (Pubitemid 40943924)
36. Li CK, Hoffmann TJ, Hsieh PY, et al. The Xylum Clot Signature Analyzer: A dynamic flow system that simulates vascular injury. Thromb Res 1998;92:S67-77 (Pubitemid 29012766)
37. FrickeW,Kouides P, Kessler C, et al.Amulticenter clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2004;2:763-68 (Pubitemid 40185715)
38. Simon DI, Liu CB, Ganz P, et al. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter Cardiovasc Interv 2001;52:425-32 (Pubitemid 32275029)
39. Harrison P. Platelet function analysis. Blood Rev 2005;19:111-23 (Pubitemid 39643116)
40. Campbell J, Ridgway H, Carville D. Plateletworks: A novel point of care platelet function screen. Mol Diagn Ther 2008;12:253-58
41. Harle CC. Point-of-care platelet function testing. Semin Cardiothorac Vasc Anesth 2007;11:247-51 (Pubitemid 351189311)
42. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009;101:333-39
43. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-62
44. Braunwald E, Angiolillo D, Bates E, et al. Antiplatelet therapy and platelet function testing: Introduction. Clin Cardiol 2008;31(3 supple 1):I1
45. Mukherjee D, Chew DP, Robbins M, et al. Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. J Thromb Thrombolysis 2001;11:151-54 (Pubitemid 32691215)
46. Jacopo G, Elisabetta V, Silverio S, et al. Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis. Thromb Res 2007;121:407-12
47. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-26 (Pubitemid 38353000)
48. Buch AN, Singh S, Roy P, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2007;99:1518-22 (Pubitemid 46770633)
49. Gulmez O, Yildirir A, Kaynar G, et al. Effects of persistent platelet reactivity despite aspirin therapyoncardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. J Thromb Thrombolysis 2008;25:239-46 (Pubitemid 351772725)
50. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-17 (Pubitemid 46891710)
51. Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009;104:525-30
52. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011; 305:1097-105
53. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention. A time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: Impact on thrombosis and safety (GRAVITAS) trial. Circulation 2011:124:1132-7
54. Eshtehardi P, Windecker S, Cook S, et al. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J 2010;159:891-98 e1
55. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52:734-39
56. Tavassoli N, Voisin S, Carrie D, et al. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Am J Cardiovasc Drugs 2010;10:29-35
57. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study. Am Heart J 2009;157:733-39
58. Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009;119:3207-14
59. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250-56
60. Pandya DJ, Fitzsimmons BF, Wolfe TJ, et al. Measurement of antiplatelet inhibition during neurointerventional procedures: The effect of antithrombotic duration and loading dose. J Neuroimaging 2010;20:64-69
61. Lee DH, Arat A, Morsi H, et al. Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: A single-center experience. AJNR Am J Neuroradiol 2008;29:1389-94
62. Qureshi AI, Siddiqui AM, Hanel RA, et al. Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: A prospective registry. Neurosurgery 2004;54:307-16, discussion 316-17